KINNATE BIOPHARMA INC (KNTE)
US49705R1059 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to KNTE. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 2.41. This target is -9.04% below the current price.
KNTE was analyzed by 10 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about KNTE.
In the previous month the buy percentage consensus was at a similar level.
KNTE was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-02-26 | Stifel | Maintains | Hold -> Hold |
| 2024-01-17 | Wedbush | Reiterate | Neutral -> Neutral |
| 2023-09-19 | Wedbush | Downgrade | Outperform -> Neutral |
| 2023-09-19 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-09-19 | Jefferies | Maintains | Buy -> Buy |
| 2023-09-19 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2023-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-12 | Stifel | Maintains | Hold -> Hold |
| 2023-05-12 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-04-20 | HC Wainwright & Co. | Maintains | Buy |
| 2023-04-19 | Goldman Sachs | Maintains | Buy |
| 2023-04-18 | Goldman Sachs | Maintains | Buy |
| 2023-03-20 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-16 | Stifel | Maintains | Hold |
| 2023-03-16 | Wedbush | Maintains | Outperform |
| 2022-11-17 | Stifel | Downgrade | Buy -> Hold |
| 2022-07-28 | HC Wainwright & Co. | Initiate | Buy |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-05-19 | Piper Sandler | Maintains | Overweight |
| 2021-09-27 | Jefferies | Initiate | Buy |
| 2021-09-23 | Stifel | Initiate | Buy |
| 2021-07-13 | William Blair | Initiate | Outperform |